Inactive Instrument

Press Releases Sensidose AB

Equities

SENSI

SE0017232671

Press Releases

Unlock all the news: Be the first to know and act before the market!

Updated recommendation by the nomination committee of Navamedic ASA	31/23/31	AQ
Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	26/23/26	AQ
Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer	26/23/26	AQ
EQL Pharma AB publishes the final outcome in public takeover offer. As a result of the shareholder dynamics and other circumstances the Board also announces its intention to sell its holdings.	17/23/17	AQ
Navamedic ASA Q1 2023: Another strong quarter	11/23/11	AQ
Navamedic increases the consideration to SEK 8.50 in cash per share in its unconditional public offer and convenes an extraordinary general meeting of Sensidose Aktiebolag	10/23/10	AQ
Navamedic publishes a supplement to the offer document regarding the unconditional cash offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag	28/23/28	AQ
Navamedic increases the consideration to SEK 0.60 in cash per warrant of series TO 1 in its unconditional offer to the warrant holders in Sensidose Aktiebolag	26/23/26	AQ
EQL Pharma extends the unconditional offer to include warrants series TO 1 and publishes a supplementary offer document regarding EQL Pharma's offer to the shareholders of Sensidose	26/23/26	AQ
Navamedic ASA expands its offer to include warrants of series TO 1 issued by Sensidose Aktiebolag at a price of SEK 0.38 in cash per warrant of series TO 1	26/23/26	AQ
Correction: Navamedic publishes a supplement to the offer document regarding the cash offer to the shareholders of Sensidose Aktiebolag	25/23/25	AQ
Navamedic publishes a supplement to the offer document regarding the recommended cash offer to the shareholders of Sensidose Aktiebolag	25/23/25	AQ
Offer document regarding EQL Pharma's offer to the shareholders of Sensidose Aktiebolag published	25/23/25	AQ
EQL Pharma AB announces a revised unconditioned cash offer of SEK 8.40 per share to the shareholders of Sensidose Aktiebolag	24/23/24	AQ
Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB	22/23/22	AQ
Navamedic completes the offer, has entered into agreements to acquire approximately 56.7 per cent of the shares in Sensidose and increases the consideration to SEK 8 in cash per share	22/23/22	AQ
EQL Pharma AB announces a recommended cash offer of SEK 7.60 per share to the shareholders of Sensidose Aktiebolag	20/23/20	AQ
Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million	29/23/29	AQ
Navamedic ASA announces a unanimously recommended cash offer of SEK 6.27 per share to the shareholders of Sensidose Aktiebolag	29/23/29	AQ
BioStock: Sensidose is growing and sees opportunities in Finland	17/23/17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sensidose AB

Equities

SENSI

SE0017232671

Press Releases

Filters